Back

Soluble ST2 is strongly associated with outcomes in pulmonary arterial hypertension

21 May 2023 (10:26 - 10:37)
Organised by: Logo
Congress Presentation Part of: Pulmonary circulation Pulmonary Hypertension HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Kaspar Broch

Oslo University Hospital Rikshospitalet, Oslo (Norway)

3 More presentations in this session

Presentation thumbnail
Long-term outcome of patients with transposition of the great arteries and a systemic right ventricle: a systematic review and meta-analysis
Doctor M. Ansari Ramandi (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Right ventricular reverse remodeling after pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
Doctor H. Ravnestad (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension due to left heart disease: first validation of the 2022 definitions in a prospective study, the PH-HF multicenter study
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary circulation
Video

The Event

Event poster

Heart Failure 2023

21 May 2023 10:26 CET
You may be interested in
thumbnail
Congress Presentation
Pathophysiological pathways related to elevated soluble ST2 concentrations and survival in patients with heart failure
thumbnail
Congress Session
Phenotyping and risk stratification in pulmonary arterial hypertension
thumbnail
Congress Session
Pulmonary hypertension: evolving strategies in diagnosis and management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources